Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).Materials and Methods. A Mar...
Main Authors: | S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2020-08-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/383 |
Similar Items
-
UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
by: Tebboth A, et al.
Published: (2016-11-01) -
Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2017-11-01) -
Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study
by: Kawachi S, et al.
Published: (2019-05-01) -
Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01) -
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
by: Hoogendoorn M, et al.
Published: (2019-02-01)